BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 23433444)

  • 21. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
    Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
    Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limb-sparing in patients with non-metastatic high-grade osteosarcoma.
    Samardziski M; Zafiroski G; Tolevska C; Zafirova-Ivanovska B; Kostadinova-Kunovska S; Kalicanin-Markovska M
    J BUON; 2009; 14(1):63-9. PubMed ID: 19373949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
    J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of large osteosarcoma in children: new approach.
    Kobys VL; Konovalenko VF; Repinа NV; Golovko TS; Gulak LO; Tarasova TO; Zaharycheva EV; Matyushok OF
    Exp Oncol; 2013 Jun; 35(2):105-8. PubMed ID: 23828385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
    Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
    J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma.
    Longhi A; Macchiagodena M; Vitali G; Bacci G
    J Pediatr Hematol Oncol; 2003 Apr; 25(4):292-6. PubMed ID: 12679642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
    J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response.
    Ferrari S; Mercuri M; Picci P; Bertoni F; Brach del Prever A; Tienghi A; Mancini A; Longhi A; Rimondini S; Donati D; Manfrini M; Ruggieri P; Biagini R; Bacci G
    Tumori; 1999; 85(6):458-64. PubMed ID: 10774566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neoadjuvant treatment in osteosarcomas].
    Kalifa C; Brugières L; Le Deley MC
    Bull Cancer; 2006 Nov; 93(11):1115-20. PubMed ID: 17145581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
    Le Deley MC; Guinebretière JM; Gentet JC; Pacquement H; Pichon F; Marec-Bérard P; Entz-Werlé N; Schmitt C; Brugières L; Vanel D; Dupoüy N; Tabone MD; Kalifa C;
    Eur J Cancer; 2007 Mar; 43(4):752-61. PubMed ID: 17267204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
    Bacci G; Longhi A; Forni C; Fabbri N; Briccoli A; Barbieri E; Mercuri M; Balladelli A; Ferrari S; Picci P
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):505-11. PubMed ID: 17118571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
    Piperno-Neumann S; Ray-Coquard I; Occean BV; Laurence V; Cupissol D; Perrin C; Penel N; Bompas E; Rios M; Le Cesne A; Italiano A; Anract P; de Pinieux G; Collard O; Bertucci F; Duffaud F; Le Deley MC; Delaye J; Brugieres L; Blay JY
    Int J Cancer; 2020 Jan; 146(2):413-423. PubMed ID: 31246277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial.
    Ferguson WS; Harris MB; Goorin AM; Gebhardt MC; Link MP; Shochat SJ; Siegal GP; Devidas M; Grier HE
    J Pediatr Hematol Oncol; 2001; 23(6):340-8. PubMed ID: 11563767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
    Ferrari S; Palmerini E; Staals E; Abate ME; Longhi A; Cesari M; Balladelli A; Pratelli L; Bacci G
    J Chemother; 2009 Apr; 21(2):205-10. PubMed ID: 19423475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
    Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
    Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
    Patel SJ; Lynch JW; Johnson T; Carroll RR; Schumacher C; Spanier S; Scarborough M
    Am J Clin Oncol; 2002 Oct; 25(5):489-95. PubMed ID: 12393991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
    J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Goal and results of the COSS study].
    Flege S; Bielack S
    Handchir Mikrochir Plast Chir; 2004 Oct; 36(5):282-8. PubMed ID: 15503258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
    Gaspar N; Occean BV; Pacquement H; Bompas E; Bouvier C; Brisse HJ; Castex MP; Cheurfa N; Corradini N; Delaye J; Entz-Werlé N; Gentet JC; Italiano A; Lervat C; Marec-Berard P; Mascard E; Redini F; Saumet L; Schmitt C; Tabone MD; Verite-Goulard C; Le Deley MC; Piperno-Neumann S; Brugieres L; ; ;
    Eur J Cancer; 2018 Jan; 88():57-66. PubMed ID: 29190507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.